The Late-Stage Protective Effect of Mito-TEMPO against Acetaminophen-Induced Hepatotoxicity in Mouse and Three-Dimensional Cell Culture Models.

CCAAT/enhancer binding protein homologous protein ER stress Mito-TEMPO acetaminophen c-jun N-terminal kinases endoplasmic reticulum liver injury mitochondria

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
09 Oct 2020
Historique:
received: 18 09 2020
accepted: 06 10 2020
entrez: 14 10 2020
pubmed: 15 10 2020
medline: 15 10 2020
Statut: epublish

Résumé

An overdose of acetaminophen (APAP), the most common cause of acute liver injury, induces oxidative stress that subsequently causes mitochondrial impairment and hepatic necroptosis. N-acetyl-L-cysteine (NAC), the only recognized drug against APAP hepatotoxicity, is less effective the later it is administered. This study evaluated the protective effect of mitochondria-specific Mito-TEMPO (Mito-T) on APAP-induced acute liver injury in C57BL/6J male mice, and a three dimensional (3D)-cell culture model containing the human hepatoblastoma cell line HepG2. The administration of Mito-T (20 mg/kg, i.p.) 1 h after APAP (400 mg/kg, i.p.) injection markedly attenuated the APAP-induced elevated serum transaminase activity and hepatic necrosis. However, Mito-T treatment did not affect key factors in the development of APAP liver injury including the activation of c-jun N-terminal kinases (JNK), and expression of the transcription factor C/EBP homologous protein (CHOP) in the liver. However, Mito-T significantly reduced the APAP-induced increase in the hepatic oxidative stress marker, nitrotyrosine, and DNA fragmentation. Mito-T markedly attenuated cytotoxicity induced by APAP in the HepG2 3D-cell culture model. Moreover, liver regeneration after APAP hepatotoxicity was not affected by Mito-T, demonstrated by no changes in proliferating cell nuclear antigen formation. Therefore, Mito-T was hepatoprotective at the late-stage of APAP overdose in mice.

Identifiants

pubmed: 33050213
pii: antiox9100965
doi: 10.3390/antiox9100965
pmc: PMC7601533
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Japan Society for the Promotion of Science
ID : KAKENHI grant numbers 21790524
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI grant numbers 23790603
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI grant numbers 26460629
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI grant numbers 17K08955
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : he Program for Leading Graduate Schools "HIGO (Health life science: Interdisciplinary and Glocal Oriented) Program

Références

Chem Res Toxicol. 1998 Jun;11(6):604-7
pubmed: 9625727
FASEB J. 2019 Dec;33(12):13905-13919
pubmed: 31645120
Drug Metab Dispos. 2002 Apr;30(4):446-51
pubmed: 11901099
Oncogene. 1998 Apr 23;16(16):2141-50
pubmed: 9572495
Toxicol Sci. 2017 Feb;155(2):363-378
pubmed: 28123000
Transl Res. 2018 Jun;196:31-41
pubmed: 29548626
Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):810-8
pubmed: 21796717
Free Radic Biol Med. 2008 Apr 1;44(7):1406-19
pubmed: 18206669
J Biol Chem. 2008 May 16;283(20):13565-77
pubmed: 18337250
J Pharmacol Exp Ther. 1990 Dec;255(3):935-41
pubmed: 2262912
Chem Biol Interact. 2009 May 15;179(2-3):273-9
pubmed: 19014921
Int J Biochem Cell Biol. 2018 Apr;97:98-103
pubmed: 29454114
Gastroenterology. 2012 Aug;143(2):307-20
pubmed: 22705006
Biomed Res Int. 2016;2016:1952947
pubmed: 27891510
Arch Toxicol. 1994;68(2):110-8
pubmed: 8179480
Brain Circ. 2018 Jul-Sep;4(3):84-94
pubmed: 30450413
J Cell Biochem. 2017 Oct;118(10):3130-3141
pubmed: 27862231
Liver Int. 2012 Jan;32(1):8-20
pubmed: 21745276
Pharm Res. 2013 Sep;30(9):2174-87
pubmed: 23462933
Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165583
pubmed: 31676378
Front Pharmacol. 2019 Sep 20;10:1092
pubmed: 31620005
Mutat Res. 2005 Jan 6;569(1-2):101-10
pubmed: 15603755
Nature. 2014 Jan 16;505(7483):335-43
pubmed: 24429632
Pharmacol Res. 2014 Sep;87:26-41
pubmed: 24951965
Toxicol Appl Pharmacol. 1988 May;93(3):378-87
pubmed: 3368917
Redox Biol. 2016 Dec;10:148-156
pubmed: 27744120
J Hepatol. 2013 Sep;59(3):495-503
pubmed: 23665281
Hepatology. 2011 Mar;53(3):974-82
pubmed: 21319200
Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):398-405
pubmed: 16294364
Hepatology. 2015 Jan;61(1):326-36
pubmed: 25142022
Toxicol Sci. 2003 Oct;75(2):458-67
pubmed: 12883092
BMC Gastroenterol. 2013 Jan 30;13:21
pubmed: 23363429
Hepatology. 2011 Feb;53(2):718-9
pubmed: 21274895
Arch Toxicol. 2017 Feb;91(2):761-773
pubmed: 27002509
J Pharmacol Sci. 2014;124(2):218-29
pubmed: 24492462
Hepatology. 2011 Sep 2;54(3):969-78
pubmed: 21626531
J Biol Chem. 1996 May 17;271(20):12063-7
pubmed: 8662637
J Clin Invest. 2012 Apr;122(4):1574-83
pubmed: 22378043
Toxicol Appl Pharmacol. 1997 Mar;143(1):1-12
pubmed: 9073586
Biomaterials. 2015 Mar;45:115-23
pubmed: 25662501
Pharmacol Res. 2015 Sep;99:52-62
pubmed: 26005208
J Pharmacol Exp Ther. 2012 Jan;340(1):134-42
pubmed: 22001257
Drug Metab Rev. 2012 Feb;44(1):88-106
pubmed: 22229890
Br J Clin Pharmacol. 2011 Feb;71(2):273-82
pubmed: 21219409
Toxicol Appl Pharmacol. 2014 Sep 15;279(3):266-274
pubmed: 24905542
J Hepatol. 2017 Dec;67(6):1324-1331
pubmed: 28734939
Med Sci Monit. 2018 Feb 28;24:1225-1231
pubmed: 29488473
Clin Sci (Lond). 2018 Jan 11;132(1):111-125
pubmed: 29212786
Nutr Res Pract. 2017 Apr;11(2):97-104
pubmed: 28386382
Toxicol Appl Pharmacol. 2013 Jun 15;269(3):240-9
pubmed: 23571099
Lancet. 2010 Jul 17;376(9736):190-201
pubmed: 20638564
Drug Saf. 2005;28(3):227-40
pubmed: 15733027
J Clin Invest. 1992 Jul;90(1):196-203
pubmed: 1634608
Crit Care. 2012 Jan 16;16(1):R9
pubmed: 22248080
Arch Intern Med. 1981 Feb 23;141(3 Spec No):380-5
pubmed: 7469629
Philos Trans R Soc Lond B Biol Sci. 1985 Dec 17;311(1152):633-45
pubmed: 2869522
Clin Liver Dis. 2007 Aug;11(3):525-48, vi
pubmed: 17723918
J Exp Med. 2012 Feb 13;209(2):307-18
pubmed: 22291093
J Immunol. 2006 May 15;176(10):6245-53
pubmed: 16670335
Nat Rev Drug Discov. 2018 Dec;17(12):865-886
pubmed: 30393373
Toxicol Sci. 2016 Dec;154(2):214-226
pubmed: 27562556
Crit Care. 2009;13(2):R55
pubmed: 19358737
Pain Med. 2010 Mar;11(3):369-78
pubmed: 20447306
Toxicol Sci. 2002 Jun;67(2):322-8
pubmed: 12011492
Toxicol Lett. 2015 Apr 16;234(2):139-50
pubmed: 25704631
Biol Pharm Bull. 2009 Jul;32(7):1215-9
pubmed: 19571388
Cell Death Dis. 2013 May 09;4:e626
pubmed: 23661004
Br J Clin Pharmacol. 2012 Feb;73(2):285-94
pubmed: 22106945
Arch Toxicol. 2019 Jan;93(1):163-178
pubmed: 30324313

Auteurs

Mohammad Abdullah-Al-Shoeb (M)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program", Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Biochemistry and Molecular Biology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.

Kenta Sasaki (K)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Saori Kikutani (S)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Nanami Namba (N)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Keiichi Ueno (K)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Yuki Kondo (Y)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Hitoshi Maeda (H)

Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Toru Maruyama (T)

Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Tetsumi Irie (T)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program", Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Yoichi Ishitsuka (Y)

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Classifications MeSH